Quinoxaline-containing compounds as hepatitis C virus inhibitors

Patent metadata

Field	Value
Publication number	US-8951998-B2
Application number	US-201213657555-A
Country	US
Kind code	B2
Filing date	Oct 22, 2012
Priority date	Nov 14, 2007
Publication date	Feb 10, 2015
Grant date	Feb 10, 2015

Abstract

The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

First claim

What is claimed:

1. A compound of Formula I or II:

or a pharmaceutically acceptable salt or ester thereof, wherein
A is absent or selected from —(C═O)—, —S(O) 2 , —C═N—OR 1 or —C(═N—CN);
L 201 is absent or selected from —C 1 -C 8 alkylene, —C 2 -C 8 alkenylene, or —C 2 -C 8 alkynylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; s…

Assignees

• Enanta Pharm Inc

Inventors

• Gai Yonghua
• Or Yat Sun
• Wang Zhe

Classifications

• A61P31/12

  Human Necessities · mapped topic

• A61P43/00

  Human Necessities · mapped topic

• A61P31/14

  Human Necessities · mapped topic

• C07K5/0827

  Chemistry & Metallurgy · mapped topic

• C07D498/22

  Chemistry & Metallurgy · mapped topic